ONCY net incomeQ2 2026-$9.44M
ONCY net income was -$9.44M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.28M a year earlier. For the full fiscal 2025 it was -$28.76M, compared with -$22.79M in fiscal 2024.
Oncolytics Biotech Inc. (ONCY) financials
For fiscal 2025 (ended Dec 31, 2025), Oncolytics Biotech Inc. reported -$28.76M of net income.
- Net income, FY2025
- -$28.76M
- Free cash flow, FY2025
- -$20.12M
- EPS, diluted, FY2025
- -$0.30
- Cash
- $4.12M
- Market cap
- $49.5M
FY2016FY2017
FY2024FY2025
FY2024FY2025
ONCY revenue and earnings growth
ONCY EPSQ2 2026-$0.08
ONCY diluted EPS was -$0.08 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.06 a year earlier. For the full fiscal 2025 it was -$0.30, compared with -$0.30 in fiscal 2024.
ONCY free cash flowQ2 2026-$8.14M
ONCY free cash flow was -$8.14M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.11M a year earlier. For the full fiscal 2025 it was -$20.12M, compared with -$20.06M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|
| Revenue | - | - | $6.18M | $0 |
| Research and development | $13.31M | $15.44M | - | - |
| Selling, general and admin | $15.41M | $10.10M | - | - |
| Operating income | -$28.73M | -$25.54M | - | - |
| Pre-tax income | -$28.68M | -$22.70M | - | - |
| Income tax | $79.0K | $95.0K | - | - |
| Net income | -$28.76M | -$22.79M | - | - |
| EPS, basic | -$0.30 | -$0.30 | - | - |
| EPS, diluted | -$0.30 | -$0.30 | - | - |
| Diluted shares | 95.9M | 76.5M | 13.9M | 12.6M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|
| Cash and equivalents | $5.20M | $11.08M | - | - |
| Current assets | $6.84M | $12.44M | - | - |
| Total assets | $7.58M | $13.42M | - | - |
| Current liabilities | $6.10M | $4.88M | - | - |
| Total liabilities | $11.38M | $10.12M | - | - |
| Shareholders' equity | -$3.80M | $3.30M | - | - |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|
| Operating cash flow | -$20.11M | -$19.88M | - | - |
| Capital expenditures | $6.0K | $174.0K | - | - |
| Free cash flow | -$20.12M | -$20.06M | - | - |
| Investing cash flow | -$6.0K | -$174.0K | - | - |
| Financing cash flow | $14.12M | $5.03M | - | - |
| Stock-based compensation | $3.10M | $1.98M | - | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Research and development | $4.26M | $4.55M | $1.92M | $2.80M |
| Selling, general and admin | $5.12M | $4.73M | $2.73M | $2.22M |
| Operating income | -$9.38M | -$9.28M | -$4.65M | -$5.02M |
| Pre-tax income | -$9.34M | -$9.24M | -$5.22M | -$4.71M |
| Income tax | $101.0K | $0 | $61.0K | $0 |
| Net income | -$9.44M | -$9.24M | -$5.28M | -$4.71M |
| EPS, basic | -$0.08 | -$0.08 | -$0.06 | -$0.06 |
| EPS, diluted | -$0.08 | -$0.08 | -$0.06 | -$0.06 |
| Diluted shares | 119.7M | 112.3M | 91.0M | 84.6M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Cash and equivalents | $4.12M | $5.49M | $10.72M | $10.64M |
| Current assets | $7.07M | $7.49M | - | - |
| Total assets | $7.67M | $8.16M | - | - |
| Current liabilities | $5.22M | $5.42M | - | - |
| Total liabilities | $13.84M | $13.29M | - | - |
| Shareholders' equity | -$6.17M | -$5.13M | $3.70M | $3.73M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Operating cash flow | -$8.14M | -$7.29M | -$4.11M | -$4.73M |
| Capital expenditures | $0 | $6.0K | $0 | $1.0K |
| Free cash flow | -$8.14M | -$7.30M | -$4.11M | -$4.73M |
| Investing cash flow | $0 | -$6.0K | $0 | -$1.0K |
| Financing cash flow | $6.77M | $7.61M | $4.09M | $4.18M |
| Stock-based compensation | $1.79M | $2.30M | $362.0K | $845.0K |
Key ratios
Source: XBRL data Oncolytics Biotech Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ONCY peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ONCY | - | - | -$28.76M | - | $49.5M |
| LEGN | $1.03B | +64.0% | -$296.80M | -28.8% | $3.97B |
| PBYI | $231.82M | +9.4% | $23.83M | 10.3% | $419.9M |
| FBIO | $68.47M | +15.5% | $111.82M | 163.3% | $63.7M |
| MBRX | $0 | - | -$30.33M | - | $8.5M |
ONCY FAQ
6 questionsIs ONCY profitable?
No. Oncolytics Biotech Inc. reported a net loss of $28.76M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ONCY have?
Oncolytics Biotech Inc. reported $4.12M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ONCY free cash flow?
Oncolytics Biotech Inc. generated -$20.12M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$20.11M less capital expenditures.What is ONCY earnings per share?
Diluted earnings per share were -$0.30 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did ONCY last report financial results?
The latest statements here come from Oncolytics Biotech Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this ONCY financial data come from?
Quantisnow builds these statements from the structured XBRL data Oncolytics Biotech Inc. files with the SEC. It is provided for information only and is not investment advice.